Professor Michael Good AO
Position
Director
Contact
The Queensland Institute of Medical Research
The Bancroft Centre
PO Royal Brisbane Hospital, QLD, 4029
Tel: 61+7+3362 0266
Fax: 61+7+3362 0110
Email: Michael.Good@qimr.edu.au
Web: www.qimr.edu.au
Research interests
My research interests are in the field of immunity and immunopathogenesis to malaria and group A streptococcus/ rheumatic fever, with particular relevance to the development of vaccines.
Qualifications
BSc(Med) (High Distinction) (Q'ld, 1975), MBBS (First Class Hons) (Q'ld, 1978), PhD (WEHI, Melb, 1983), MD (Q'ld, 1986), DSc (Q'ld, 1991), FASM (1992), FAFPHM (1992), FRACP (Hon) (2000), FAIM (2001), FRACMA (2007)
Ten Most Significant Publications
1. Good, M. F., Maloy, W. L., Lunde, M. N., Margalit, H., Cornette, J., Smith, G. L., Moss, B., Miller, L. H., and Berzofsky, J. A.: Construction of a synthetic immunogen: use of a new T-helper epitope on malaria circumsporozite protein. Science 235: 1059-1062, 1987.
2. Kumar, S., Miller, L. H., Quakyi, I. A., Keister, D. B., Houghten, R. A., Maloy, W. L., Moss, B., Berzofsky, J. A., and Good, M. F.: Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature 334: 258-260, 1988.
3. Good, M. F., Miller, L. H., Kumar, S., Quakyi, I. A., Keister, D., Adams, J. H., Moss, B., Berzofsky, J. A., and Carter, R.: Limited immunological recognition of critical malaria vaccine candidate antigens. Science 242: 574-577, 1988.
4. Pruksakorn, S., Currie, B., Brandt, E., Martin, D., Galbraith, A., Phornphutkul, C., Hunsakunachai, S., Manmontri, A., and Good, M.F.: Towards a vaccine for rheumatic fever: identification of a conserved target epitope on the M protein of group A streptococci. The Lancet (article) 344:639-642, 1994.
5. Brandt, E.R., Sriprakash, K.S., Hobb, R.I., Hayman, W.A., Weiguang Zeng, Batzloff, M.R., Jackson, D.C., and Good, M.F. Novel multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nature Medicine 6: 455-459, 2000.
6. Pombo, D.J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., Anderson, K., Mahakunkijcharoen, Y., Elliott, S., Eisen, D.P., Saul, A., and Good, M.F. Immunity to malaria in humans following administration of ultra-low doses of Plasmodium falciparum-infected red cells. The Lancet 360: 610-617, 2002.
7. Makobongo, M.O., Riding, G., Xu, H., Keough, D., de Jersey, J., Willadsen, P. and Good, M.F. The purine salvage enzyme, HGXPRT, is a major target antigen for cell-mediated immunity to malaria. Proc. Natl. Acad. Sci. USA 100: 2628 2633, 2003.
8. Good, M.F., Xu, H., Wykes, M., and Engwerda, C.R. Development and regulation of cell-mediated immune responses to the blood stages of malaria: Implications for vaccine research. Ann. Rev. Immunol. 23: 69-99, 2005.
9. Good, M.F. and Doolan, D.L. Malaria's journal through the lymph node. Nature Medicine 13: 1023-1024, 2007.
10. Engwerda, C.R. and Good, M.F. Disarming the malaria parasite. Nature Medicine 14: 912-913, 2008.
Currently Held Grants
Heart Foundation (G 08B 3838) (M GOOD, M PANDEY, T NORDSTROM, M BATZLOFF) "Design and analysis of an improved vaccine candidate against rheumatic heart disease" 2009-2010
Merck (M GOOD, M BATZLOFF), 2007-2009
GlaxoSmithKline Post Graduate Support Grant (M GOOD, A PINZON-CHARRY) "A malaria vaccine using low doses of dead parasite and CpG oligodeoxynucleotide", 2008-2009
NHMRC Program Funding (D KEMP, MF GOOD, D MCMANUS, I TOTH, N ANSTEY, S SRIPRAKASH, D DOOLAN, C ENGWERDA, A LOUKAS) "Immunity and pathogenesis in Tropical and Infectious Diseases: Implications for Vaccines and Drug Development", 2008-2012
|
